Public Employees Retirement System of Ohio lowered its holdings in PerkinElmer, Inc. (NYSE:PKI) by 29.0% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 71,571 shares of the medical research company’s stock after selling 29,177 shares during the period. Public Employees Retirement System of Ohio owned approximately 0.06% of PerkinElmer worth $6,895,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Quadrant Capital Group LLC acquired a new stake in shares of PerkinElmer in the first quarter valued at approximately $25,000. Amica Retiree Medical Trust bought a new position in PerkinElmer during the 2nd quarter worth $48,000. Coastal Capital Group Inc. acquired a new position in PerkinElmer in the 2nd quarter valued at $58,000. Signaturefd LLC raised its holdings in PerkinElmer by 171.5% in the 1st quarter. Signaturefd LLC now owns 809 shares of the medical research company’s stock valued at $78,000 after acquiring an additional 511 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC bought a new stake in shares of PerkinElmer during the 2nd quarter valued at $78,000. 95.19% of the stock is owned by hedge funds and other institutional investors.
In other news, Director Alexis P. Michas sold 2,000 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $82.56, for a total value of $165,120.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.80% of the company’s stock.
Shares of PKI stock traded up $0.85 on Wednesday, hitting $86.35. 22,855 shares of the company’s stock were exchanged, compared to its average volume of 578,512. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.89 and a quick ratio of 1.31. PerkinElmer, Inc. has a 12 month low of $71.83 and a 12 month high of $103.00. The stock has a market cap of $9.31 billion, a P/E ratio of 23.95, a price-to-earnings-growth ratio of 1.49 and a beta of 1.29. The company has a 50 day moving average of $84.45 and a 200 day moving average of $91.49.
PerkinElmer (NYSE:PKI) last released its quarterly earnings data on Monday, July 29th. The medical research company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.01). The business had revenue of $722.50 million during the quarter, compared to analyst estimates of $729.10 million. PerkinElmer had a net margin of 9.01% and a return on equity of 16.07%. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period last year, the business earned $0.91 earnings per share. Sell-side analysts predict that PerkinElmer, Inc. will post 4.04 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, November 8th. Shareholders of record on Friday, October 18th will be given a $0.07 dividend. The ex-dividend date is Thursday, October 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.32%. PerkinElmer’s dividend payout ratio is currently 7.76%.
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Featured Story: What is the quiet period?
Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.